GemVax Applies for Phase 3 Clinical Trial of Alzheimer's Disease Treatment

[Asia Economy Reporter Ji Yeon-jin] GemVax announced on the 27th that it has applied for approval of the Phase 3 clinical trial plan for GV1001, an Alzheimer's disease treatment, in South Korea.

The company stated, "There is a possibility that the clinical trial and product approval process may yield results that do not meet expectations, and accordingly, the company may change or abandon its commercialization plans. Investors are advised to carefully consider the disclosed investment risks comprehensively through timely disclosures and business reports before making investment decisions."